Abstract:Premature atherosclerosis, the hallmark of cardiovascular diseases, has been found to be a significant cause of late deaths in systemic lupus erythematosus (SLE) patients. Therefore, early identification of atherosclerosis before the overt disease is curial for the management program of SLE. Flow-mediated dilatation (FMD%) is a reliable, noninvasive, easy to use, reproducible, and pathogenically relevant index for early atherosclerosis. In recent years, a number of studies have been performed to compare the mean FMD% difference between patients with SLE and healthy controls. However, these studies have shown inconclusive or even contradictory findings. In this study, to derive a more precise comparison of FMD% difference between SLE patients and healthy controls, a meta-analysis was performed. Databases were searched to identify all available studies comparing FMD% between SLE patients and healthy controls. The study eligibility criteria were cohort or case–control studies with data on both patients diagnosed with SLE and healthy controls, and use of high-resolution ultrasonography to detect FMD. Random effect meta-analysis was conducted to evaluate the overall mean FMD% difference between the two groups. Publication bias was detected by funnel plot and Egger’s test. Meta-regression analysis was performed to investigate the potential influencing factors on FMD% difference. Of the 434 articles initially identified, 22 were finally included in the meta-analysis. Compared to healthy controls, SLE patients had significantly lower FMD% (standardized mean difference, −1.19; 95 % CI, −1.63, −0.74; P < 0.001). There was significant heterogeneity among these studies ( I 2 = 94.3 %, P < 0.001), which was mainly due to variations in disease duration of SLE patients. The funnel plot showed a skewed shape, indicating a marked publication bias, which was further supported by the Egger’s test ( P = 0.006). However, after the correction for potential publication bias by using the trim-and-fill method, the main results for all studies combined were still significant ( P < 0.001). Taken together, these findings support the current evidence on a higher cardiovascular burden in SLE and support using FMD% as a surrogate for premature atherosclerosis in SLE patients.

The significance of quantitative measurement of Fas receptor molecules expression on T lymphocytes surface in the treatment of systemic lupus erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

The correlation between quantitative expression of Fas receptor molecules on CD3+ T lymphocyte and disease activity of systemic lupus erythematosus

Peripheral CD24hi CD27+ CD19+ B Cells Subset As a Potential Biomarker in Naïve Systemic Lupus Erythematosus.

[Clinical Significance of CD4+CD25+ T Cells in Peripheral Blood of Patients in Systemic Lupus Erythematosus].

Abnormal Expression of Cd43 in Patients with Systemic Lupus Erythematosus and Its Clinical Significance

Changes in the Expression of Fas on T Lymphocytes after Allogeneic Fetal Thymus Transplantation in Systemic Lupus Erytematosus Mice.

Decreased Flow-Mediated Dilatation in Patients with Systemic Lupus Erythematosus: a Meta-analysis

Frequency and Significance of CD4+CD25+T Cell Subpopulations in the Peripheral Blood of Patients with Systemic Lupus Erythematosus

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

Association of serum soluble Fas,apoptosis and indices of the damage of organ or system in systemic lupus erythematosus

Levels of Soluble Interleukin-2 Receptor and Clinical Significance in Patients with Systemic Lupus Erythematosus

Identification and Characterization of CD8+CD27+CXCR3− T Cell Dysregulation and Progression‐Associated Biomarkers in Systemic Lupus Erythematosus

[Role of Circulating T Follicular Helper Subsets and T Follicular Helper Effector Memory Cells in Systemic Lupus Erythematosus].

Analysis of Peripheral Blood CD8+ Regulatory Lymphocytes from the Patients with Systemic Lupus Erythematosus

The Effects of Dexamethason on Apoptosis and Expressions of Fas,FasL in Peripheral Blood Lymphocytes from Patients with Systemic Lupus Erythematosus

Significance of CD69/CD3 Ratio of Peripheral Blood Mononuclear Cells As a Marker for Evaluating the Disease Activity of Systemic Lupus Erythematosus

Imbalance of Different Types of CD4+forkhead Box Protein 3 (foxp3)+ T Cells in Patients with New-Onset Systemic Lupus Erythematosus

Correlation between levels of dendritic cell subsets in systemic lupus erythematosus patients and SLEDAI

Study of T-lymphocyte Activation and Correlation with Disease Activity in Patients with Systemic Lupus Erythematosus